Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Citrate, Norflex Orphenadrine
2. Citrate, Orphenadrine
3. Disipal
4. Hydrochloride, Orphenadrine
5. Lysantin
6. Mefenamine
7. Mefenamine, Sodium
8. Mephenamine
9. Methyldiphenylhydramine
10. Norflex
11. Norflex Orphenadrine Citrate
12. Orphenadrine
13. Orphenadrine Citrate, Norflex
14. Orphenadrine Hydrochloride
15. Sodium Mefenamine
1. 4682-36-4
2. Norflex
3. Banflex
4. Orphenadrine Dihydrogen Citrate
5. Flexon
6. Orphenadrine (citrate)
7. Flexoject
8. X-otag
9. Orphenadrine Citrate Salt
10. 2-hydroxypropane-1,2,3-tricarboxylic Acid; Dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine
11. 4596-23-0
12. Nsc-757238
13. Orphenadrine Citrate [usp]
14. N,n-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic Acid
15. Orphenadrine Citrate (norflex)
16. Chebi:7790
17. X0a40n8i4s
18. N,n-dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamine 2-hydroxypropane-1,2,3-tricarboxylate
19. Ncgc00094745-01
20. Plenactol
21. Euflex
22. Flexor
23. Tega-flex
24. Orphenadrine Citrate (usp)
25. Dsstox_cid_24678
26. Dsstox_rid_80390
27. Dsstox_gsid_44678
28. Norflex (pharmaceutical)
29. Orphenadrinecitrate
30. N,n-dimethyl-2-(phenyl(o-tolyl)methoxy)ethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate
31. Cas-4682-36-4
32. Einecs 225-137-5
33. Unii-x0a40n8i4s
34. Norflex (tn)
35. Orphenadine Citrate
36. N,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate (1:1)
37. Ethanamine, N,n-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
38. Mls000069549
39. Schembl119470
40. Spectrum1500447
41. Chembl1200395
42. Dtxsid8044678
43. Hms502k15
44. Hy-b0369a
45. Orphenadrine Citrate [mi]
46. Hms1920d10
47. Hms2091l10
48. Hms2231j06
49. Hms3259m21
50. Hms3370m12
51. Hms3651a10
52. Hms3884m22
53. Pharmakon1600-01500447
54. Citric Acid; N,n-dimethyl-2-[o-tolyl(phenyl)methoxy]ethanamine
55. O-methyldiphenhydramine Citrate Salt
56. Orphenadrine Citrate [vandf]
57. Tox21_111323
58. Tox21_113543
59. Tox21_301079
60. Ccg-40242
61. Nsc757238
62. Orphenadrine Citrate [mart.]
63. Orphenadrine Citrate [who-dd]
64. Akos008132385
65. Tox21_111323_1
66. Nc00525
67. Nsc 757238
68. (+-)-n,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate (1:1)
69. Ethylamine, N,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)-, Citrate (1:1)
70. Ncgc00015771-13
71. Ncgc00094745-02
72. Ncgc00094745-03
73. Ncgc00254980-01
74. As-74807
75. Ethanamine, N,n-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, (+-)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
76. Orphenadrine Citrate [ep Impurity]
77. Orphenadrine Citrate [orange Book]
78. Smr000058817
79. Orphenadrine Citrate [ep Monograph]
80. Orphenadrine Citrate [usp Monograph]
81. Ft-0655842
82. Ft-0673305
83. S2054
84. Sw102176-4
85. En300-53019
86. Norgesic Component Orphenadrine Citrate
87. C75247
88. D00774
89. Invagesic Component Orphenadrine Citrate
90. Orphenadrine Citrate Component Of Norgesic
91. Orphengesic Component Orphenadrine Citrate
92. A826945
93. Orphenadrine Citrate Component Of Invagesic
94. Orphenadrine Citrate Component Of Orphengesic
95. Sr-01000002975-5
96. Invagesic Forte Component Orphenadrine Citrate
97. Orphengesic Forte Component Orphenadrine Citrate
98. Q27107584
99. Orphenadrine Citrate Component Of Invagesic Forte
100. Orphenadrine Citrate Component Of Orphengesic Forte
101. Beta-dimethylaminoethyl 2-methylbenzhydryl Ether Citrate Salt
102. N,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate
103. (+-)-n,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate
104. (+/-)-n,n-dimethyl-2-((o-methyl-.alpha.-phenylbenzyl)oxy)ethylamine Citrate (1:1)
105. Ethanamine, N,n-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, (+/-)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
106. Ethanamine, N,n-dimethyl-2-[(2-methylphenyl)phenylmethoxy]-,2-hydroxy-1,2,3-propanetricarboxylate (1:1)
107. N,n-dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine 2-hydroxypropane-1,2,3-tricarboxylate
| Molecular Weight | 461.5 g/mol |
|---|---|
| Molecular Formula | C24H31NO8 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 11 |
| Exact Mass | 461.20496695 g/mol |
| Monoisotopic Mass | 461.20496695 g/mol |
| Topological Polar Surface Area | 145 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 488 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Norflex |
| PubMed Health | Orphenadrine |
| Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
| Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2- methylbenzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly solubl... |
| Active Ingredient | Orphenadrine citrate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 30mg/ml |
| Market Status | Prescription |
| Company | Medicis |
| 2 of 4 | |
|---|---|
| Drug Name | Orphenadrine citrate |
| PubMed Health | Orphenadrine Citrate/Aspirin/Caffeine (By mouth) |
| Drug Classes | Skeletal Muscle Relaxant, Centrally Acting/Salicylate, Aspirin Combination |
| Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate i... |
| Active Ingredient | Orphenadrine citrate |
| Dosage Form | Tablet, extended release; Injectable |
| Route | Injection; Oral |
| Strength | 30mg/ml; 100mg |
| Market Status | Prescription |
| Company | Impax Pharms; Tedor Pharma; Sandoz; Invagen Pharms; Watson Labs; Gavis Pharms; Sagent Pharms; Eurohlth Intl; Akorn |
| 3 of 4 | |
|---|---|
| Drug Name | Norflex |
| PubMed Health | Orphenadrine |
| Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
| Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2- methylbenzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly solubl... |
| Active Ingredient | Orphenadrine citrate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 30mg/ml |
| Market Status | Prescription |
| Company | Medicis |
| 4 of 4 | |
|---|---|
| Drug Name | Orphenadrine citrate |
| PubMed Health | Orphenadrine Citrate/Aspirin/Caffeine (By mouth) |
| Drug Classes | Skeletal Muscle Relaxant, Centrally Acting/Salicylate, Aspirin Combination |
| Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate i... |
| Active Ingredient | Orphenadrine citrate |
| Dosage Form | Tablet, extended release; Injectable |
| Route | Injection; Oral |
| Strength | 30mg/ml; 100mg |
| Market Status | Prescription |
| Company | Impax Pharms; Tedor Pharma; Sandoz; Invagen Pharms; Watson Labs; Gavis Pharms; Sagent Pharms; Eurohlth Intl; Akorn |
Cytochrome P-450 CYP2B6 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2B6. (See all compounds classified as Cytochrome P-450 CYP2B6 Inhibitors.)
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Muscle Relaxants, Central
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
M - Musculo-skeletal system
M03 - Muscle relaxants
M03B - Muscle relaxants, centrally acting agents
M03BC - Ethers, chemically close to antihistamines
M03BC01 - Orphenadrine (citrate)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7108
Submission : 1987-08-11
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-12-16
Pay. Date : 2013-07-05
DMF Number : 5722
Submission : 1985-02-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4811
Submission : 1983-01-21
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4457
Submission : 1982-02-08
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2942
Submission : 1977-05-09
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-11-13
Pay. Date : 2014-10-31
DMF Number : 14971
Submission : 2000-07-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38456
Submission : 2023-06-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33901
Submission : 2019-05-29
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7837
Submission : 1988-12-20
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
Orphenadrine Citrate BP/USP/EP
Date of Issue : 2019-07-29
Valid Till : 2022-07-29
Written Confirmation Number : WC-0445
Address of the Firm : Plot No. IP No. 27-29, Parts of Sy. Nos 18, 273, 274 & 313, KIADB Industrial Ar...
Orphenadrine Citrate USP/BP/EP
Date of Issue : 2019-07-22
Valid Till : 2022-07-22
Written Confirmation Number : WC-0139
Address of the Firm : # 15, KHB Industrial Area, Yelahanka, Bangalore-560 064
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Sweden
Brand Name : Norflex
Dosage Form : PROLONGED-RELEASE TABLET
Dosage Strength : 100 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Disipal
Dosage Form : Orphenadrine 50Mg 50 Combined Oral Use
Dosage Strength : 50 cpr riv 50 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Controlled & Modified Release
Granulation
Disintegrants & Superdisintegrants
Lubricants & Glidants
Thickeners and Stabilizers
Co-Processed Excipients
Film Formers & Plasticizers
Taste Masking
Solubilizers
Chewable & Orodispersible Aids
Parenteral
Empty Capsules
Vegetarian Capsules
API Stability Enhancers
Emulsifying Agents
Rheology Modifiers
Coloring Agents
Topical
Surfactant & Foaming Agents
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
A Orphenadrine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orphenadrine, including repackagers and relabelers. The FDA regulates Orphenadrine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orphenadrine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Orphenadrine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Orphenadrine supplier is an individual or a company that provides Orphenadrine active pharmaceutical ingredient (API) or Orphenadrine finished formulations upon request. The Orphenadrine suppliers may include Orphenadrine API manufacturers, exporters, distributors and traders.
click here to find a list of Orphenadrine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Orphenadrine DMF (Drug Master File) is a document detailing the whole manufacturing process of Orphenadrine active pharmaceutical ingredient (API) in detail. Different forms of Orphenadrine DMFs exist exist since differing nations have different regulations, such as Orphenadrine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Orphenadrine DMF submitted to regulatory agencies in the US is known as a USDMF. Orphenadrine USDMF includes data on Orphenadrine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Orphenadrine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Orphenadrine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Orphenadrine Drug Master File in Korea (Orphenadrine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Orphenadrine. The MFDS reviews the Orphenadrine KDMF as part of the drug registration process and uses the information provided in the Orphenadrine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Orphenadrine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Orphenadrine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Orphenadrine suppliers with KDMF on PharmaCompass.
A Orphenadrine CEP of the European Pharmacopoeia monograph is often referred to as a Orphenadrine Certificate of Suitability (COS). The purpose of a Orphenadrine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Orphenadrine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Orphenadrine to their clients by showing that a Orphenadrine CEP has been issued for it. The manufacturer submits a Orphenadrine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Orphenadrine CEP holder for the record. Additionally, the data presented in the Orphenadrine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Orphenadrine DMF.
A Orphenadrine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Orphenadrine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Orphenadrine suppliers with CEP (COS) on PharmaCompass.
A Orphenadrine written confirmation (Orphenadrine WC) is an official document issued by a regulatory agency to a Orphenadrine manufacturer, verifying that the manufacturing facility of a Orphenadrine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Orphenadrine APIs or Orphenadrine finished pharmaceutical products to another nation, regulatory agencies frequently require a Orphenadrine WC (written confirmation) as part of the regulatory process.
click here to find a list of Orphenadrine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Orphenadrine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Orphenadrine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Orphenadrine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Orphenadrine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Orphenadrine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Orphenadrine suppliers with NDC on PharmaCompass.
Orphenadrine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Orphenadrine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Orphenadrine GMP manufacturer or Orphenadrine GMP API supplier for your needs.
A Orphenadrine CoA (Certificate of Analysis) is a formal document that attests to Orphenadrine's compliance with Orphenadrine specifications and serves as a tool for batch-level quality control.
Orphenadrine CoA mostly includes findings from lab analyses of a specific batch. For each Orphenadrine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Orphenadrine may be tested according to a variety of international standards, such as European Pharmacopoeia (Orphenadrine EP), Orphenadrine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orphenadrine USP).
LOOKING FOR A SUPPLIER?
